Clinical Trials Browser

Metastatic Digestive System Neuroendocrine Tumor G1

Lymphoma, Multiple Myeloma

Neoplasm Metastasis, Osteosarcoma

Uveal Melanoma

Lymphoma, Non-Hodgkin, Multiple Myeloma

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Sarcoma, Alveolar Soft Part

Carcinoma, Renal Cell, Urologic Neoplasms

Prostatic Neoplasms

Carcinoma, Renal Cell

Sarcoma, Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

Somatostatinoma

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Carcinoma, Renal Cell

Advanced Rare Tumours

Colorectal Neoplasms

Gastrointestinal Stromal Tumors

Carcinoma, Renal Cell

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Thymoma, Thymus Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Carcinoma, Renal Cell

Carcinoma, Renal Cell, Kidney Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Carcinoma, Renal Cell, Neoplasm Metastasis

Paraganglioma

Stomach Neoplasms

Carcinoma, Renal Cell

Brain Neoplasms, Gliosarcoma

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

Small Cell Lung Carcinoma

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Carcinoma, Renal Cell, Neoplasm Metastasis

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Clear-cell metastatic renal cell carcinoma

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Renal Cell

Carcinoma, Renal Cell

Carcinoma, Renal Cell

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Clinical Trials

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

CAPTUR

MOMENTUM-1

TAPUR

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

LUMEN-1

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

OCCLURANDOM

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Sunitinib and Capecitabine for First Line Colon Cancer

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

ASSET

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase II Study of Alternating Sunitinib and Temsirolimus

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

MERECA

FIRSTMAPPP

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Sunitinib in Sarcomas of the Central Nervous System

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

SURF

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

NIVOSWITCH

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

BIONIKK

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

INMUNOSUN

TAURUS

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

IIT Sutent